Dementia and Alzheimer Disease

Eleonora Tornatore-Mikesh, chief executive officer of CaringKind, The Heart of Alzheimer's Caregiving, and an anonymous caregiver, spoke about their perspective with caring for a loved one who has been diagnosed with Alzheimer disease.

After showing inconsistent results in previous trials, AVP-786 did not demonstrate statistically significant outcomes vs placebo on the primary outcome of change in Cohen-Mansfield Agitation Inventory.

Here's some of what is coming soon to NeurologyLive® this week.

A recent study highlighted the elevated risk of liver diseases, particularly hepatic encephalopathy, in veterans with dementia who lacked a cirrhosis diagnosis.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders, and specifically, Duchenne muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 9, 2024.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Neurology News Network for the week ending February 3, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 2, 2024.

In a recent open-label trial, utilization of focused ultrasound to open the blood–brain barrier combined with infusions of aducanumab decreased amyloid-β levels.

Approved in 2021 under the accelerated approval pathway, aducanumab’s path has been met with controversy and lack of industry support.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders.

A systematic approach to understanding the needs of the caregiving youth—a growing and less-studied population of caregivers—is needed to better tailor interventions, provide support, and improve care to patients and their families.

Neurology News Network for the week ending January 27, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 26, 2024.

The chief executive officer of Aruna Bio provided context on a newly accepted phase 1/2 trial assessing the company’s neural-derived exosome agent AB126 in patients with acute ischemic stroke.

The director of Geriatric Psychiatry at the St Louis University School of Medicine talked about BXCL501 as a potential treatment for acute agitation in patients with Alzheimer disease and how it compares with brexpiprazole, the first approved therapy. [WATCH TIME: 4 minutes]

Overall, the results revealed that light therapy helped to alleviate sleep efficiency, sleep quality, depressed mood, caregiver burden, and agitated behavior.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Neurology News Network for the week ending January 21, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 19, 2024.

The strong association observed at APOE in this analysis was consistent with observations from other amyloid-lowering therapies, which also found an elevated incidence of ARIA among APOE ε4 carriers.